Food for thought

Immunotoxicology: Challenges in the 21st century and in vitro opportunities

Thomas Hartung, Emanuela Corsini

Research output: Contribution to journalArticle

Abstract

Over the last two decades, little has changed in the practice of immunotoxicity testing for regulatory purposes, especially for immunosuppression, and autoimmunity is still a challenge. Current guidelines still rely on animal tests, which include some immune endpoints in repeated dose tests and trigger dedicated tests only when certain alerts indicate a problem. At the same time, however, a wealth of in vitro approaches has been developed, but few have been adopted for routine testing. The extent to which immunotoxicity of chemicals represents a health problem for the human population at low levels of exposure is unclear: it appears that responses of healthy individuals to immunological challenges differ widely and most immunomodulators have few adverse effects except when they coincide with an infectious or malignant challenge or when early in life exposure is expected, in which cases the odds of progressing into infection, autoimmune diseases, or cancer can be changed. The enormous overcapacity of immune defense, the presence of compensatory mechanisms, and their fast restoration each contribute to limiting health threats for the individual, though on a population base also minor immunomodulation may result in increased morbidity. In vitro alternative approaches may allow screening for problematic substances and prioritize them for in vivo testing. New approaches are emerging from mapping pathways of immunotoxicity. Increasingly, the contribution of inflammatory and infectious components to the adverse outcome pathways of chemicals is recognized for various hazards, urging inclusion of tests for proinflammatory and immunomodulatory properties of chemicals into integrated testing strategies.

Original languageEnglish (US)
Pages (from-to)411-426
Number of pages16
JournalAltex
Volume30
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Immunomodulation
Health
Immunologic Factors
Autoimmunity
Immunosuppression
Population
Autoimmune Diseases
Guidelines
Morbidity
Infection
Neoplasms
In Vitro Techniques

Keywords

  • Alternative methods
  • Immune system
  • Toxicity testing
  • Toxicology for the 21 century
  • Xenobiotics

ASJC Scopus subject areas

  • Medical Laboratory Technology
  • Pharmacology

Cite this

Food for thought : Immunotoxicology: Challenges in the 21st century and in vitro opportunities. / Hartung, Thomas; Corsini, Emanuela.

In: Altex, Vol. 30, No. 4, 2013, p. 411-426.

Research output: Contribution to journalArticle

@article{0a5427f5bc37466c920db3900b7af4cc,
title = "Food for thought: Immunotoxicology: Challenges in the 21st century and in vitro opportunities",
abstract = "Over the last two decades, little has changed in the practice of immunotoxicity testing for regulatory purposes, especially for immunosuppression, and autoimmunity is still a challenge. Current guidelines still rely on animal tests, which include some immune endpoints in repeated dose tests and trigger dedicated tests only when certain alerts indicate a problem. At the same time, however, a wealth of in vitro approaches has been developed, but few have been adopted for routine testing. The extent to which immunotoxicity of chemicals represents a health problem for the human population at low levels of exposure is unclear: it appears that responses of healthy individuals to immunological challenges differ widely and most immunomodulators have few adverse effects except when they coincide with an infectious or malignant challenge or when early in life exposure is expected, in which cases the odds of progressing into infection, autoimmune diseases, or cancer can be changed. The enormous overcapacity of immune defense, the presence of compensatory mechanisms, and their fast restoration each contribute to limiting health threats for the individual, though on a population base also minor immunomodulation may result in increased morbidity. In vitro alternative approaches may allow screening for problematic substances and prioritize them for in vivo testing. New approaches are emerging from mapping pathways of immunotoxicity. Increasingly, the contribution of inflammatory and infectious components to the adverse outcome pathways of chemicals is recognized for various hazards, urging inclusion of tests for proinflammatory and immunomodulatory properties of chemicals into integrated testing strategies.",
keywords = "Alternative methods, Immune system, Toxicity testing, Toxicology for the 21 century, Xenobiotics",
author = "Thomas Hartung and Emanuela Corsini",
year = "2013",
doi = "10.14573/altex.2013.4.411",
language = "English (US)",
volume = "30",
pages = "411--426",
journal = "ALTEX : Alternativen zu Tierexperimenten",
issn = "1868-596X",
publisher = "Elsevier GmbH",
number = "4",

}

TY - JOUR

T1 - Food for thought

T2 - Immunotoxicology: Challenges in the 21st century and in vitro opportunities

AU - Hartung, Thomas

AU - Corsini, Emanuela

PY - 2013

Y1 - 2013

N2 - Over the last two decades, little has changed in the practice of immunotoxicity testing for regulatory purposes, especially for immunosuppression, and autoimmunity is still a challenge. Current guidelines still rely on animal tests, which include some immune endpoints in repeated dose tests and trigger dedicated tests only when certain alerts indicate a problem. At the same time, however, a wealth of in vitro approaches has been developed, but few have been adopted for routine testing. The extent to which immunotoxicity of chemicals represents a health problem for the human population at low levels of exposure is unclear: it appears that responses of healthy individuals to immunological challenges differ widely and most immunomodulators have few adverse effects except when they coincide with an infectious or malignant challenge or when early in life exposure is expected, in which cases the odds of progressing into infection, autoimmune diseases, or cancer can be changed. The enormous overcapacity of immune defense, the presence of compensatory mechanisms, and their fast restoration each contribute to limiting health threats for the individual, though on a population base also minor immunomodulation may result in increased morbidity. In vitro alternative approaches may allow screening for problematic substances and prioritize them for in vivo testing. New approaches are emerging from mapping pathways of immunotoxicity. Increasingly, the contribution of inflammatory and infectious components to the adverse outcome pathways of chemicals is recognized for various hazards, urging inclusion of tests for proinflammatory and immunomodulatory properties of chemicals into integrated testing strategies.

AB - Over the last two decades, little has changed in the practice of immunotoxicity testing for regulatory purposes, especially for immunosuppression, and autoimmunity is still a challenge. Current guidelines still rely on animal tests, which include some immune endpoints in repeated dose tests and trigger dedicated tests only when certain alerts indicate a problem. At the same time, however, a wealth of in vitro approaches has been developed, but few have been adopted for routine testing. The extent to which immunotoxicity of chemicals represents a health problem for the human population at low levels of exposure is unclear: it appears that responses of healthy individuals to immunological challenges differ widely and most immunomodulators have few adverse effects except when they coincide with an infectious or malignant challenge or when early in life exposure is expected, in which cases the odds of progressing into infection, autoimmune diseases, or cancer can be changed. The enormous overcapacity of immune defense, the presence of compensatory mechanisms, and their fast restoration each contribute to limiting health threats for the individual, though on a population base also minor immunomodulation may result in increased morbidity. In vitro alternative approaches may allow screening for problematic substances and prioritize them for in vivo testing. New approaches are emerging from mapping pathways of immunotoxicity. Increasingly, the contribution of inflammatory and infectious components to the adverse outcome pathways of chemicals is recognized for various hazards, urging inclusion of tests for proinflammatory and immunomodulatory properties of chemicals into integrated testing strategies.

KW - Alternative methods

KW - Immune system

KW - Toxicity testing

KW - Toxicology for the 21 century

KW - Xenobiotics

UR - http://www.scopus.com/inward/record.url?scp=84893129066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893129066&partnerID=8YFLogxK

U2 - 10.14573/altex.2013.4.411

DO - 10.14573/altex.2013.4.411

M3 - Article

VL - 30

SP - 411

EP - 426

JO - ALTEX : Alternativen zu Tierexperimenten

JF - ALTEX : Alternativen zu Tierexperimenten

SN - 1868-596X

IS - 4

ER -